<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.159003.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Quantification of hepatitis B viral load in patients attending healthcare facilities in Gezira state, Sudan</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: awaiting peer review]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Zakaria</surname>
                        <given-names>Altayib</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Eltaib</surname>
                        <given-names>Hadia</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Elsanousi</surname>
                        <given-names>Yasir</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-5735-5230</uri>
                    <xref ref-type="corresp" rid="c2">b</xref>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Department of Medical Microbiology, AL Managil University, AL Managil, Gezira, Sudan</aff>
                <aff id="a2">
                    <label>2</label>Department of Medical Microbiology, Shendi University, Shendi, Sudan</aff>
                <aff id="a3">
                    <label>3</label>Division of Medical and Health Services &amp; Research, Alsabeel Charitable Health Center (SCHC), Omdurman, Sudan</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:altayibzakaria30666@gmail.com">altayibzakaria30666@gmail.com</email>
                </corresp>
                <corresp id="c2">
                    <label>b</label>
                    <email xlink:href="mailto:yasir3@yahoo.com">yasir3@yahoo.com</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>26</day>
                <month>11</month>
                <year>2024</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2024</year>
            </pub-date>
            <volume>13</volume>
            <elocation-id>1432</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>20</day>
                    <month>11</month>
                    <year>2024</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2024 Zakaria A et al.</copyright-statement>
                <copyright-year>2024</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/13-1432/pdf"/>
            <abstract>
                <title>Abstract</title>
                <sec>
                    <title>Background</title>
                    <p>Hepatitis B virus (HBV) infection remains a significant global health challenge particularly in developing countries and regions. Gezira State, Sudan where prevalence and disease burden are high is an example of such regions. This study aimed to quantify HBV viral load among patients in Gezira State and assess the distribution of viral loads across demographic groups, including gender and age.</p>
                </sec>
                <sec>
                    <title>Method</title>
                    <p>A descriptive cross-sectional study was conducted between January 2022 and January 2023. Randomly selected 100 chronic HBV patients were enrolled from major healthcare facilities in Wad Medani, Gezira&#x2019;s capital. Viral loads were measured using real-time PCR, and statistical analyses were performed to identify predictors of high viral load.</p>
                </sec>
                <sec>
                    <title>Results</title>
                    <p>The results revealed that the mean HBV viral load was 886,363 IU/ml (SD&#x00b1; 421,295), with a significantly higher mean in males (1,122,899 IU/ml) compared to females (531,559 IU/ml) (p&lt; 0.0001). Viral loads ranged from 15 IU/ml to 35,474,488 IU/ml, with 37% of patients exceeding the WHO-recommended treatment threshold of 2,000 IU/ml. However, no significant association was found between viral load and age (p=0.939).</p>
                </sec>
                <sec>
                    <title>Conclusion</title>
                    <p>The study highlighted the need for gender-specific management strategies and the importance of HBV viral load quantification for effective public health intervention in Gezira State. Further research is recommended to explore HBV epidemiology in Sudan more comprehensively.</p>
                </sec>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>hepatitis B</kwd>
                <kwd>viral hepatitis</kwd>
                <kwd>HBV</kwd>
                <kwd>virus</kwd>
                <kwd>viral load</kwd>
                <kwd>PCR</kwd>
                <kwd>Sudan</kwd>
                <kwd>Gezira</kwd>
            </kwd-group>
            <funding-group>
                <funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec id="sec5" sec-type="intro">
            <title>Introduction</title>
            <p>Hepatitis B virus (HBV) infection still stands as a major global public health problem, especially in developing countries where the prevalence and morbidity rates are relatively high. World Health Organization (WHO) estimated that about 254 million people globally were living with chronic HBV infection in 2022, and most of these cases were found in low-and middle income countries.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>
                </sup> Moreover, HBV is a leading cause of cirrhosis of the liver and hepatocellular carcinoma (HCC), which contribute greatly to mortality as well as morbidity related to the liver.
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>&#x2013;
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup> There is a need for a comprehensive understanding of its epidemiology and management.</p>
            <p>Quantification of HBV viral load is an important factor in the clinical management of HBV infection, helping in making decisions concerning eligibility for therapy and antiviral prophylaxis, and informing about disease development and possibility of transmission.
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>&#x2013;
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup> It involves measuring the concentration of HBV DNA within a person&#x2019;s blood, which mirrors viral replication activity. Higher levels are associated with more liver inflammation, fibrosis progress as well as greater chances to develop HCC.
                <sup>
                    <xref ref-type="bibr" rid="ref11">11</xref>
                </sup> Assessing of the viral load levels is useful not only for managing patients but also for tracking public health response activities. When more individuals have high viral loads, it means they are actively transmitting the virus leading to possibilities of outbreaks thus making targeted public health responses necessary.
                <sup>
                    <xref ref-type="bibr" rid="ref12">12</xref>
                </sup>
            </p>
            <p>Within Sudan, Gezira State located centrally has been identified as one such region with significant burden of HBV infection. Studies conducted in Gezira State indicate that chronic HBV infection is highly prevalent and together with its long-term complications such as liver cirrhosis and hepatocellular carcinoma represents a significant public health challenge.
                <sup>
                    <xref ref-type="bibr" rid="ref13">13</xref>
                </sup>
            </p>
            <p>Gezira State is one of Sudan&#x2019;s most populous regions in Sudan. It includes densely populated areas and a large number of people who are going from rural to urban areas that support HBV transmission.
                <sup>
                    <xref ref-type="bibr" rid="ref14">14</xref>
                </sup> The state is distinguished by the presence of large-scale national irrigation schemes, a fact that rendered its epidemiological profile for HBV transmission a complex one. Migration patterns, the presence of diverse demographic groups resembling rural-urban disparities, difficulties in healthcare access, and fragile socioeconomic settings are some of the factors that influence the spread and management of HBV in this state and contribute further complexity to HBV epidemiology forcing disease control measures to be specifically targeted rather than universal.</p>
            <p>There are limited data on the levels of HBV viral loads in patients of Gezira State despite their significance. This paucity of knowledge is very crucial as it limits the development of effective public health policies and clinical interventions that are tailored to fit into local epidemiology. Besides, there is a necessity to comprehend demographic and clinical factors that associate with viral load to identify populations at risk and optimize HBV resource allocation.</p>
            <p>The aim of this study was to quantify HBV viral load among patients with HBV infection in Gezira State; and to analyze the distribution of viral loads among different demographic groups. It also attempted to identify possible predictors of high viral load which can be used for risk stratification and tailored therapeutic strategies.</p>
        </sec>
        <sec id="sec6" sec-type="methods">
            <title>Methods</title>
            <sec id="sec7">
                <title>Study area</title>
                <p>This study was conducted in the city of Wad Medani, the capital of Gezira state in central Sudan. Gezira state (
                    <xref ref-type="fig" rid="f1">
Figure 1</xref>) expands in an area of 25,549 km
                    <sup>2</sup> and encompasses eight localities with total population of 5,096,920.
                    <sup>
                        <xref ref-type="bibr" rid="ref15">15</xref>
                    </sup>
                </p>
                <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                    <label>
Figure 1. </label>
                    <caption>
                        <title>Map of the Republic of Sudan showing Gezira state (in green).</title>
                    </caption>
                    <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/174671/036b1e67-cd57-431e-a2d6-15f68e9408c8_figure1.gif"/>
                </fig>
                <p>The city of Wad Medani resembles the focal point of specialized healthcare with its multitude of advanced facilities and laboratories in government and private sectors. HBV patients of all Gezira state localities attend there (mostly referred) for diagnosis, treatment and follow-up of their condition.</p>
            </sec>
            <sec id="sec8">
                <title>Study design</title>
                <p>This descriptive cross-sectional study was conducted from Jan 2022 to Jan 2023 on chronic HBV patients attending healthcare facilities in Gezira state (Wad Medani Teaching hospital, Blue Nile Institute for Endemic Diseases, El Tamioz Medical Laboratories, and private hepatology clinics). One hundred HBV patients were enrolled in this study; their selection was random depending on their presence and acceptance to participate.</p>
            </sec>
            <sec id="sec9">
                <title>Inclusion and exclusion criteria</title>
                <p>Inclusion criteria for a participant were that they should: (a) be an already diagnosed chronic hepatitis B patient, (b) be a resident of Gezira state, and (c) have signed the informed consent. Participants were excluded if: (a) they were newly diagnosed or acute hepatitis patients, (b) they were not residents of Gezira state, and (c) they did not agree to participate or did not sign the informed consent.</p>
            </sec>
            <sec id="sec10">
                <title>Laboratory procedures</title>
                <p>A sample of 2.5 ml of venous blood was aseptically collected from the cubital fossa of each participant and dispensed into sterile lithium heparin containers. Plasma was stored at -20&#x00b0;C; then HBV DNA was extracted using the QIAampMinElute Virus Spin Kit (Qiagen, Hilden, Germany). DNA was purified from 200 &#x03bc;L of serum and eluted in 60 &#x03bc;L elution buffer. DNA level in the blood was detected by the real-time fluorescent quantitative polymerase chain reaction (PCR) (DaAn Gene, Guangzhou, China) on ABI7500 (Applied Biosystems, Foster City, USA).</p>
            </sec>
            <sec id="sec11">
                <title>Statistical analysis</title>
                <p>Descriptive statistics were performed in analyzing the obtained data. All data collected in this study were tabulated, coded, and ordered using Microsoft
                    <sup>&#x00ae;</sup> Office Excel
                    <sup>&#x00ae;</sup> 2007 (12.0.4518) Statistical analysis was done by using the online MedCalc Software, Ostend, Belgium Version 23.0.2 (
                    <ext-link ext-link-type="uri" xlink:href="https://www.medcalc.org/calc/comparison_of_means.php">https://www.medcalc.org/calc/comparison_of_means.php</ext-link>) for the comparison of means to test the difference in viral load by gender; and iCalcu online tool (
                    <ext-link ext-link-type="uri" xlink:href="https://www.icalcu.com/stat/chisqtest.html">https://www.icalcu.com/stat/chisqtest.html</ext-link>) in performing two-way Chi-squared test to find the relationship between age (in groups) and viral load values (in categories). All statistical analysis tools were done at 95% confidence interval; p value &#x2264; 0.05 was considered significant.</p>
            </sec>
        </sec>
        <sec id="sec12" sec-type="results">
            <title>Results</title>
            <p>Of the 100 hepatitis B patients included in this study, 40 (40%) were female and 60 (60%) were male (
                <xref ref-type="table" rid="T1">
Table 1</xref>). Ages of participants ranged between 16 years and 70 years (mean 40 years). Viral load values ranged from 15 IU/ml to 35,474,488 IU/ml. The mean HBV viral load of all the 100 participants was 886,363 IU/ml (SD&#x00b1;421,295). Comparison of the mean viral loads by gender revealed a significant difference between the two: mean viral load of males alone was 1,122,899 IU/ml) (SD&#x00b1; 510,342), while that of the female category was 531,559 IU/ml (SD&#x00b1; 233,208) (p &lt; 0.0001). Distribution of viral load ranges among patients according to gender revealed that the highest viral load range (&gt;1,000,000 IU/ml) was detected in five males (5%) and three females (3%), with total 8 (8%) of the study population. The lowest viral load range (0-100 IU/ml) was detected in 15 males (15%) and nine females (9%) with total 24 (24%) of study population. 
                <xref ref-type="table" rid="T1">
Table 1</xref> shows distribution of all ranges by gender.</p>
            <table-wrap id="T1" orientation="portrait" position="float">
                <label>
Table 1. </label>
                <caption>
                    <title>Distribution of viral load ranges among male and female patient groups by number and proportion.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="2" valign="top">Viral load (IU/ml)</th>
                            <th align="left" colspan="2" rowspan="1" valign="top">Gender</th>
                            <th align="left" colspan="1" rowspan="2" valign="top">
Total n (%)</th>
                        </tr>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top">Male n (%)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
Female n (%)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">0&#x2013;100</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">15 (15.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">9 (9.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">24 (24.0%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">101&#x2013;1,000</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">15 (15.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">16 (16.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">31 (31.0%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">1,001&#x2013;10,000</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">12(12.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">8 (8.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">20 (20.0%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">10,001&#x2013;100,000</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">8 (8.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">2 (2.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">10 (10.0%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">100,001&#x2013;1,000,000</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">5 (5.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">2 (2.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">7 (7.0%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&gt;1,000,000</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">5 (5.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">3 (3.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">8 (8.0%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">All</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">60 (60.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">40 (40.0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">100 (100.0%)</td>
                        </tr>
                    </tbody>
                </table>
                <table-wrap-foot>
                    <p>n: Number.</p>
                </table-wrap-foot>
            </table-wrap>
            <p>When categorizing the viral load values into ranges, the largest proportion of patients (31%, n=31) fell into the 101-1,000 IU/ml group (second lowest), with almost equal male: female ratio (
                <xref ref-type="table" rid="T1">
Table 1</xref>; 
                <xref ref-type="fig" rid="f2">
Figure 2</xref>). However numbers and percentages of male patients surpassed the corresponding female ones in all the other groups including the entire ranges of highest viral load (
                <xref ref-type="fig" rid="f3">
Figure 3</xref>).</p>
            <fig fig-type="figure" id="f2" orientation="portrait" position="float">
                <label>
Figure 2. </label>
                <caption>
                    <title>Distribution of patients into HBV viral load ranges by proportion.</title>
                </caption>
                <graphic id="gr2" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/174671/036b1e67-cd57-431e-a2d6-15f68e9408c8_figure2.gif"/>
            </fig>
            <fig fig-type="figure" id="f3" orientation="portrait" position="float">
                <label>
Figure 3. </label>
                <caption>
                    <title>Distribution of HBV viral load among male and female by proportion.</title>
                </caption>
                <graphic id="gr3" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/174671/036b1e67-cd57-431e-a2d6-15f68e9408c8_figure3.gif"/>
            </fig>
            <p>The viral load was also quantified in all age groups. Difference within all groups was not statistically significant (p=0.939). The highest viral load (&gt; 1.000.000 IU/ml) was detected in 0 (0%) in age group (0 - 20) years, 1 (1%) in age group 20 - 29 years, 1 (1%) in age group (30 - 39) years, 4 (4%) in age group (40 - 49) years, 1 (1%) in age group (50-59) years and 1 (1%) in age &gt; 60 years with total 8 (8%) of the study population. The lowest viral load range (0-100) IU/ml was detected in 3 (3%) in age group (0 - 20 years), 4 (4%) in age group (20-29) years, 7 (7%) in age group (30-39) years, 5 (5%) in age group (40-49) years, 5 (5%) in age group (50- 59) years and 0 (0%) in age group &gt; 60 years with total 24 (24%) of the study population. 
                <xref ref-type="table" rid="T2">
Table 2</xref> and 
                <xref ref-type="fig" rid="f4">
Figure 4</xref> show distribution of all viral load ranges among all age groups.</p>
            <table-wrap id="T2" orientation="portrait" position="float">
                <label>
Table 2. </label>
                <caption>
                    <title>Distribution of viral load ranges among age groups by number and proportion.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top">&#x2003;&#x2003;&#x2003;Age group 
(Years)</th>
                            <th align="left" colspan="1" rowspan="2" valign="top">0-20</th>
                            <th align="left" colspan="1" rowspan="2" valign="top">20 &#x2013; 29</th>
                            <th align="left" colspan="1" rowspan="2" valign="top">30 &#x2013; 39</th>
                            <th align="left" colspan="1" rowspan="2" valign="top">40 &#x2013; 49</th>
                            <th align="left" colspan="1" rowspan="2" valign="top">50 &#x2013; 59</th>
                            <th align="left" colspan="1" rowspan="2" valign="top">&gt; 60</th>
                            <th align="left" colspan="1" rowspan="2" valign="top">Total n (%)</th>
                            <th align="left" colspan="3" rowspan="1" valign="top"/>
                        </tr>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top">Viral load 
(IU/ml)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">X
                                <sup>2</sup>
                            </th>
                            <th align="left" colspan="1" rowspan="1" valign="top">DF</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">
p-value
</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">
                                <bold>0&#x2013;100</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">3 (3%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">4 (4%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">7 (7%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5 (5%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5 (5%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0 (0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">24 (24%)</td>
                            <td align="left" colspan="1" rowspan="6" valign="middle">15.077</td>
                            <td align="left" colspan="1" rowspan="6" valign="middle">25</td>
                            <td align="left" colspan="1" rowspan="6" valign="middle">0.939  (NS)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">
                                <bold>101&#x2013;1,000</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">7 (7%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">11 (11%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">6 (6%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">4 (4%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2 (2%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">31 (31%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">
                                <bold>1,001&#x2013;10,000</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2 (2%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">5 (5%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">8 (8%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2 (2%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2 (2%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">20 (20%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">
                                <bold>10,001&#x2013;100,000</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2 (2%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">3 (3%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">2 (2%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">10 (10%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">
                                <bold>100,001&#x2013;1,000,000</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0 (0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">3 (3%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">7 (7%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">
                                <bold>&gt;1,000,000</bold>
</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">0 (0%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">4 (4%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">1 (1%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">8 (8%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="middle">Total</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">8 (8%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">17 (7%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">26 (26%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">28 (28%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">14 (14%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">7 (7%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="middle">100 (100%)</td>
                            <td colspan="3" rowspan="1"/>
                        </tr>
                    </tbody>
                </table>
                <table-wrap-foot>
                    <p>n: Number; NS: Non-significant; X
                        <sup>2</sup>: Chi-squared; DF: Degree of freedom.</p>
                </table-wrap-foot>
            </table-wrap>
            <fig fig-type="figure" id="f4" orientation="portrait" position="float">
                <label>
Figure 4. </label>
                <caption>
                    <title>Distribution of HBV viral load ranges among age groups of patients.</title>
                </caption>
                <graphic id="gr4" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/174671/036b1e67-cd57-431e-a2d6-15f68e9408c8_figure4.gif"/>
            </fig>
        </sec>
        <sec id="sec13" sec-type="discussion">
            <title>Discussion</title>
            <p>The study elicited the significance of quantifying the viral load of HBV patients and came up with important data regarding the situation of HBV infection in Gezira state. The mean viral load in participants amounted to an alarmingly high level of 886,363 IU/ml (SD&#x00b1;421,295); and while the WHO recommendations of 2024
                <sup>
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup> advise commencing treatment at HBV DNA &gt;2000 IU/ml (in addition to an ALT level above the upper limit of normal), over third of the study participants (37%, n=37) had VL above this limit This warrants more attention from public health authorities in Gezira to take actions including incorporation of viral load quantitative testing in survey and management of HBV infection; and revision of treatment plans. The findings in our study were consistent with those of a research conducted in Sudan,
                <sup>
                    <xref ref-type="bibr" rid="ref16">16</xref>
                </sup> which reported closely similar variations in viral loads among patients in the region of Khartoum State.</p>
            <p>The average viral load was significantly higher in our male patients than in female patients (p&lt;0.0001). This result is in-line with several research conclusions worldwide that identified this gender disparity. A study from Taiwan found males had higher HBV viral loads than females.
                <sup>
                    <xref ref-type="bibr" rid="ref17">17</xref>
                </sup> Similarly a study from West Africa revealed a significant association between hepatitis B viral load and gender; the median viral load was higher in men than in women and males were more likely to have a higher viral load than females.
                <sup>
                    <xref ref-type="bibr" rid="ref18">18</xref>
                </sup> Another study recognized this disparity and offered an explanation that direct and indirect factors play a role in this difference. A direct factor is by the regulation of viral gene expression; the indirect by host immune responses modulation.
                <sup>
                    <xref ref-type="bibr" rid="ref19">19</xref>
                </sup>
            </p>
            <p>While the study observed a wide variation in distribution of viral load among the different age groups but it did not discover a statistically significant correlation between age and HBV viral load (p=0.939). Unlike the issue of correlation of gender with HBV load which harvested many confirmations in published research, influence of age on HBV viral load exhibited widely conflicting results across studies. Several studies reached conclusions like ours and did not establish a significant association of age with HBV viral load.
                <sup>
                    <xref ref-type="bibr" rid="ref20">20</xref>&#x2013;
                    <xref ref-type="bibr" rid="ref23">23</xref>
                </sup> On another hand, one would find several other studies on different cohorts of HBV patients, including HCC patients, ethnic groups, and people with co-infections or special conditions &#x2026; etc. that documented significant correlation between age and HBV viral load.
                <sup>
                    <xref ref-type="bibr" rid="ref24">24</xref>&#x2013;
                    <xref ref-type="bibr" rid="ref28">28</xref>
                </sup> However, despite the agreement of these studies on the significant influence of age on viral load, but notably they produced diverse results about which age group had the increasing viral load. While a study may report viral load increases with age,
                <sup>
                    <xref ref-type="bibr" rid="ref26">26</xref>
                </sup> another may conversely state that higher viral loads were predominant in much younger ages and decrease with old age.
                <sup>
                    <xref ref-type="bibr" rid="ref18">18</xref>
                </sup> Multiple studies on similar cohorts in different geographical, environmental and social situations are recommended to clarify these disparities.</p>
            <sec id="sec14">
                <title>Limitations</title>
                <p>Although the study produced valuable information and confirmed the importance of quantifying the viral load for treatment, follow-up and prophylaxis, but some limitations exist and have to be recognized. Since the study covered all the localities of Gezira state, the relatively small sample size may not be representative of all HBV-infected individuals in the entire state, including those who do not seek medical care or follow-up. Moreover, the study population was limited only to patients attending medical facilities in the capital city of Gezira, and this may affect the generalizability.</p>
            </sec>
        </sec>
        <sec id="sec15" sec-type="conclusions">
            <title>Conclusions</title>
            <p>The study realized the importance of quantitative testing of HBV DNA in HBV patients in Gezira state. The high mean HBV viral load of the studied sample (886,363 IU/ml), calls for further actions by the concerned public health authorities in Gezira state. The study found the mean viral load to be significantly higher in male gender than in females (p&lt;0.0001). Regarding age, the study did not find a statistically significant correlation between viral load and age in the studied sample. Nevertheless the study observed the presence of wide variation in viral load values amongst different age groups.</p>
            <p>Gender-specific treatment strategies and personalized care approaches are recommended in order to reduce the risk of severe liver disease and manage HBV effectively and in consistency with international guidelines. The study recommends and encourages further comprehensive and detailed research in different aspects of quantification of HBV viral load within Gezira State specifically and all other states of Sudan as general.</p>
            <sec id="sec16">
                <title>Ethics and consent</title>
                <p>The study is adherent to the Declaration of Helsinki. Ethical permission to conduct this study was granted by the Research Directorate, Ministry of Health-Gezira State, Sudan (No. P/G 44-7) issued on 3/1/2022. Explanation of the purpose of the study, and assurance of confidentiality were presented to the participating patients. Written informed consent was obtained from each participant prior to their inclusion in the study.</p>
            </sec>
        </sec>
    </body>
    <back>
        <sec id="sec19" sec-type="data-availability">
            <title>Data availability</title>
            <p>Zenodo: Quantification of hepatitis B viral load in patients attending healthcare facilities in Gezira state, Sudan. 
                <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.14062595">https://doi.org/10.5281/zenodo.14062595</ext-link>
                <sup>
                    <xref ref-type="bibr" rid="ref29">29</xref>
                </sup>
            </p>
            <p>This project contains the following underlying data:
                <list list-type="bullet">
                    <list-item>
                        <label>&#x2022;</label>
                        <p>
HBV_VL_GZ_Dataset.xlsx (Demographic data and HBV viral load values of the participants, sorted in separate worksheets according to code, gender, age and VL respectively)</p>
                    </list-item>
                </list>
            </p>
            <p>Data are available under the terms of the 
                <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link> (CC-BY 4.0).</p>
        </sec>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <label>1</label>
                <mixed-citation publication-type="other">
                    <collab>World Health Organization: Hepatitis infection</collab>:<year>2024</year>. Accessed: September 14, 2024.
                    <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news/item/09-04-2024-who-sounds-alarm-on-viral-hepatitis-infections-claiming-3500-lives-each-day">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref2">
                <label>2</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ott</surname>
                            <given-names>JJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Stevens</surname>
                            <given-names>GA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Groeger</surname>
                            <given-names>J</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity.</article-title>
                    <source>

                        <italic toggle="yes">Vaccine.</italic>
</source>
                    <year>2012</year>;<volume>30</volume>:<fpage>2212</fpage>&#x2013;<lpage>2219</lpage>.
                    <pub-id pub-id-type="pmid">22273662</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.12.116</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref3">
                <label>3</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Arzumanyan</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Reis</surname>
                            <given-names>HM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Feitelson</surname>
                            <given-names>MA</given-names>
                        </name>
</person-group>:
                    <article-title>Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma.</article-title>
                    <source>

                        <italic toggle="yes">Nat. Rev. Cancer.</italic>
</source>
                    <year>2013</year>;<volume>13</volume>:<fpage>123</fpage>&#x2013;<lpage>135</lpage>.
                    <pub-id pub-id-type="pmid">23344543</pub-id>
                    <pub-id pub-id-type="doi">10.1038/nrc3449</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <label>4</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Tarocchi</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Polvani</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Marroncini</surname>
                            <given-names>G</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis.</article-title>
                    <source>

                        <italic toggle="yes">World J. Gastroenterol.</italic>
</source>
                    <year>2014</year>;<volume>20</volume>:<fpage>11630</fpage>&#x2013;<lpage>11640</lpage>.
                    <pub-id pub-id-type="pmid">25206269</pub-id>
                    <pub-id pub-id-type="doi">10.3748/wjg.v20.i33.11630</pub-id>
                    <pub-id pub-id-type="pmcid">PMC4155355</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref5">
                <label>5</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Jiang</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Han</surname>
                            <given-names>Q</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhao</surname>
                            <given-names>H</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>The mechanisms of HBV-induced hepatocellular carcinoma.</article-title>
                    <source>

                        <italic toggle="yes">J. Hepatocell. Carcinoma.</italic>
</source>
                    <year>2021</year>;<volume>8</volume>:<fpage>435</fpage>&#x2013;<lpage>450</lpage>.
                    <pub-id pub-id-type="pmid">34046368</pub-id>
                    <pub-id pub-id-type="doi">10.2147/JHC.S307962</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8147889</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <label>6</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Rizzo</surname>
                            <given-names>GE</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Cabibbo</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Crax&#x00ec;</surname>
                            <given-names>A</given-names>
                        </name>
</person-group>:
                    <article-title>Hepatitis B virus-associated hepatocellular carcinoma.</article-title>
                    <source>

                        <italic toggle="yes">Viruses.</italic>
</source>
                    <year>2022</year>;<volume>14</volume>:<fpage>986</fpage>.
                    <pub-id pub-id-type="pmid">35632728</pub-id>
                    <pub-id pub-id-type="doi">10.3390/v14050986</pub-id>
                    <pub-id pub-id-type="pmcid">PMC9146458</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref7">
                <label>7</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Mouna</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pallier</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Proust</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Comparison of the Abbott Alinity m and m2000 assays for the quantification of HIV-1, HCV and HBV in clinical samples.</article-title>
                    <source>

                        <italic toggle="yes">J. Clin. Virol.</italic>
</source>
                    <year>2020</year>;<volume>126</volume>:<fpage>104331</fpage>.
                    <pub-id pub-id-type="pmid">32179444</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.jcv.2020.104331</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref8">
                <label>8</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Teh</surname>
                            <given-names>CP</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Chook</surname>
                            <given-names>JB</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ngeow</surname>
                            <given-names>YF</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Primer and probe conservation issue in the quantification of hepatitis B virus DNA.</article-title>
                    <source>

                        <italic toggle="yes">Rev. Med. Virol.</italic>
</source>
                    <year>2021</year>;<volume>31</volume>:<fpage>1</fpage>&#x2013;<lpage>12</lpage>.
                    <pub-id pub-id-type="doi">10.1002/rmv.2182</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref9">
                <label>9</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yoshida</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Desbiolles</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Feldman</surname>
                            <given-names>SF</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Hepatitis B core-related antigen to indicate high viral load: Systematic review and meta-analysis of 10,397 individual participants.</article-title>
                    <source>

                        <italic toggle="yes">Clin. Gastroenterol. Hepatol.</italic>
</source>
                    <year>2021</year>;<volume>19</volume>:<fpage>46</fpage>&#x2013;<lpage>60.e8</lpage>.
                    <pub-id pub-id-type="pmid">32360825</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.cgh.2020.04.045</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref10">
                <label>10</label>
                <mixed-citation publication-type="other">
                    <collab>World Health Organization</collab>:
                    <article-title>Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection.</article-title>
                    <year>2024</year>. Accessed: September 20, 2024.
                    <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789240090903">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref11">
                <label>11</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chen</surname>
                            <given-names>CJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Yang</surname>
                            <given-names>HI</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Su</surname>
                            <given-names>J</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.</article-title>
                    <source>

                        <italic toggle="yes">JAMA.</italic>
</source>
                    <year>2006</year>;<volume>295</volume>:<fpage>65</fpage>&#x2013;<lpage>73</lpage>.
                    <pub-id pub-id-type="pmid">16391218</pub-id>
                    <pub-id pub-id-type="doi">10.1001/jama.295.1.65</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref12">
                <label>12</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Liaw</surname>
                            <given-names>YF</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Chu</surname>
                            <given-names>CM</given-names>
                        </name>
</person-group>:
                    <article-title>Hepatitis B virus infection.</article-title>
                    <source>

                        <italic toggle="yes">Lancet.</italic>
</source>
                    <year>2009</year>;<volume>373</volume>:<fpage>582</fpage>&#x2013;<lpage>592</lpage>.
                    <pub-id pub-id-type="doi">10.1016/S0140-6736(09)60207-5</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref13">
                <label>13</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Mudawi</surname>
                            <given-names>HM</given-names>
                        </name>
</person-group>:
                    <article-title>Epidemiology of viral hepatitis in Sudan.</article-title>
                    <source>

                        <italic toggle="yes">Clin. Exp. Gastroenterol.</italic>
</source>
                    <year>2008</year>;<volume>1</volume>:<fpage>9</fpage>&#x2013;<lpage>13</lpage>.
                    <pub-id pub-id-type="doi">10.2147/ceg.s3887</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref14">
                <label>14</label>
                <mixed-citation publication-type="other">
                    <collab>World Health Organization</collab>:
                    <article-title>Hepatitis B fact sheet 2019.</article-title>
                    <year>2021</year>. Accessed: October 15, 2023.
                    <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-b">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref15">
                <label>15</label>
                <mixed-citation publication-type="other">
                    <article-title>Sudan Presidency: About states.</article-title>
                    <year>2020</year>. Accessed: August 23, 2024.
                    <ext-link ext-link-type="uri" xlink:href="https://www.presidency.gov.sd/page/About-States">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref16">
                <label>16</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yousif</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Mudawi</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bakhiet</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Molecular characterization of hepatitis B virus in liver disease patients and asymptomatic carriers of the virus in Sudan.</article-title>
                    <source>

                        <italic toggle="yes">BMC Infect. Dis.</italic>
</source>
                    <year>2013</year>;<volume>13</volume>:<fpage>328</fpage>.
                    <pub-id pub-id-type="pmid">23865777</pub-id>
                    <pub-id pub-id-type="doi">10.1186/1471-2334-13-328</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3722059</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref17">
                <label>17</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Tseng</surname>
                            <given-names>TC</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>CJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Yang</surname>
                            <given-names>HC</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load.</article-title>
                    <source>

                        <italic toggle="yes">Hepatology.</italic>
</source>
                    <year>2012</year>;<volume>55</volume>:<fpage>68</fpage>&#x2013;<lpage>76</lpage>.
                    <pub-id pub-id-type="pmid">21858846</pub-id>
                    <pub-id pub-id-type="doi">10.1002/hep.24615</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref18">
                <label>18</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Diawara</surname>
                            <given-names>PS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ngom</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ndoye</surname>
                            <given-names>M</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Profiling hepatitis B viral load: Treatment and epidemiological implications in a West African hospital.</article-title>
                    <source>

                        <italic toggle="yes">Adv. Inf. Dis.</italic>
</source>
                    <year>2022</year>;<volume>12</volume>:<fpage>703</fpage>&#x2013;<lpage>714</lpage>.
                    <pub-id pub-id-type="doi">10.4236/aid.2022.124049</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref19">
                <label>19</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Nevola</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tortorella</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rosato</surname>
                            <given-names>V</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Gender differences in the pathogenesis and risk factors of hepatocellular carcinoma.</article-title>
                    <source>

                        <italic toggle="yes">Biology.</italic>
</source>
                    <year>2023</year>;<volume>12</volume>:<fpage>984</fpage>.
                    <pub-id pub-id-type="pmid">37508414</pub-id>
                    <pub-id pub-id-type="doi">10.3390/biology12070984</pub-id>
                    <pub-id pub-id-type="pmcid">PMC10376683</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref20">
                <label>20</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yim</surname>
                            <given-names>HJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lok</surname>
                            <given-names>AS</given-names>
                        </name>
</person-group>:
                    <article-title>Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005.</article-title>
                    <source>

                        <italic toggle="yes">Hepatology.</italic>
</source>
                    <year>2006</year>;<volume>43</volume>:<fpage>S173</fpage>&#x2013;<lpage>S181</lpage>.
                    <pub-id pub-id-type="pmid">16447285</pub-id>
                    <pub-id pub-id-type="doi">10.1002/hep.20956</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref21">
                <label>21</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Viana</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wang</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Yu</surname>
                            <given-names>MC</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Hepatitis B viral loads in Southern African blacks with hepatocellular carcinoma.</article-title>
                    <source>

                        <italic toggle="yes">J. Med. Virol.</italic>
</source>
                    <year>2009</year>;<volume>81</volume>:<fpage>1525</fpage>&#x2013;<lpage>1530</lpage>.
                    <pub-id pub-id-type="pmid">19623667</pub-id>
                    <pub-id pub-id-type="doi">10.1002/jmv.21574</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref22">
                <label>22</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Okwuraiwe</surname>
                            <given-names>AP</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Salu</surname>
                            <given-names>OB</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Onwuamah</surname>
                            <given-names>CK</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Experience with hepatitis B viral load testing in Nigeria.</article-title>
                    <source>

                        <italic toggle="yes">Afr. J. Cln. Exper. Microbiol.</italic>
</source>
                    <year>2011</year>;<volume>12</volume>:<fpage>101</fpage>&#x2013;<lpage>105</lpage>.
                    <pub-id pub-id-type="doi">10.4314/ajcem.v12i3.3</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref23">
                <label>23</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Sharma</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bhargava</surname>
                            <given-names>AK</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lodha</surname>
                            <given-names>KM</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Correlation of HBV-DNA viral load and serological markers (HbsAg and HBeAg) in chronic hepatitis B carriers.</article-title>
                    <source>

                        <italic toggle="yes">Int. J. Pharm. Clin. Res.</italic>
</source>
                    <year>2024</year>;<volume>16</volume>:<fpage>856</fpage>&#x2013;<lpage>860</lpage>.
                    <ext-link ext-link-type="uri" xlink:href="http://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue4,Article146.pdf">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref24">
                <label>24</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Moyen Uddin</surname>
                            <given-names>P</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rabby</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>SMK</surname>
                            <given-names>NB</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Hepatitis B viral load (HBVDNA) with age and sex stratifications in Bangladeshi people.</article-title>
                    <source>

                        <italic toggle="yes">J. Med. Microb. Diagn.</italic>
</source>
                    <year>2014</year>;<volume>03</volume>:<fpage>144</fpage>.
                    <pub-id pub-id-type="doi">10.4172/2161-0703.1000144</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref25">
                <label>25</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Tran</surname>
                            <given-names>TT</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Gordon</surname>
                            <given-names>SC</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fung</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Hepatitis B e antigen status and hepatitis B DNA levels in women of childbearing age with chronic hepatitis B infection screening for clinical trials.</article-title>
                    <source>

                        <italic toggle="yes">PLoS One.</italic>
</source>
                    <year>2015</year>;<volume>10</volume>:<fpage>e0121632</fpage>.
                    <pub-id pub-id-type="pmid">25789483</pub-id>
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0121632</pub-id>
                    <pub-id pub-id-type="pmcid">PMC4366373</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref26">
                <label>26</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Khan</surname>
                            <given-names>MA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Waqar</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rehman</surname>
                            <given-names>Z</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Hepatitis B virus (HBV) a severe health problem in Mardan, Khyber Pakhtunkhwa: A molecular based study.</article-title>
                    <source>

                        <italic toggle="yes">BioSci. Rev.</italic>
</source>
                    <year>2019</year>;<volume>01</volume>:<fpage>25</fpage>&#x2013;<lpage>32</lpage>.
                    <pub-id pub-id-type="doi">10.32350/BSR.0101.03</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref27">
                <label>27</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Jia</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Li</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wei</surname>
                            <given-names>C</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Factors associated with disease progression and viral replication in patients with chronic hepatitis B virus infection.</article-title>
                    <source>

                        <italic toggle="yes">Exp. Ther. Med.</italic>
</source>
                    <year>2019</year>;<volume>17</volume>:<fpage>4730</fpage>&#x2013;<lpage>4740</lpage>.
                    <pub-id pub-id-type="pmid">31086607</pub-id>
                    <pub-id pub-id-type="doi">10.3892/etm.2019.7482</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6489049</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref28">
                <label>28</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Khan</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Khan</surname>
                            <given-names>MI</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Khan</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Evaluation of HBeAg and HBV viral load among general population of district Bannu, Khyber Pakhtunkhwa, Pakistan.</article-title>
                    <source>

                        <italic toggle="yes">J. Adv. Pharm. Educ. Res.</italic>
</source>
                    <year>2023</year>;<volume>13</volume>:<fpage>59</fpage>&#x2013;<lpage>63</lpage>.
                    <pub-id pub-id-type="doi">10.51847/zZieCqODBE</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref29">
                <label>29</label>
                <mixed-citation publication-type="data">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Zakaria</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Eltaib</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Elsanousi</surname>
                            <given-names>Y</given-names>
                        </name>
</person-group>:
                    <data-title>Quantification of hepatitis B viral load in patients attending healthcare facilities in Gezira state, Sudan.</data-title>[Dataset].
                    <source>

                        <italic toggle="yes">Zenodo.</italic>
</source>
                    <year>2024</year>.
                    <ext-link ext-link-type="uri" xlink:href="https://zenodo.org/records/14062595">Reference Source</ext-link>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
</article>
